Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of DCV/ASV/Beclabuvir FDC in Renal Impairment
NCT02108639Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daclatasvir, asunaprevir and beclabuvir in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration and Area under the concentration-time curve in 1 dosing interval. Started Apr 2014; status: completed.
02
Drugs
daclatasvirasunaprevirbeclabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02108639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02108639.